GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Net Change in Cash

Neoleukin Therapeutics (Neoleukin Therapeutics) Net Change in Cash : $-15.48 Mil (TTM As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Neoleukin Therapeutics's Net Change in Cash for the three months ended in Sep. 2023 was $-5.88 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $-15.48 Mil.

Neoleukin Therapeutics Net Change in Cash Historical Data

The historical data trend for Neoleukin Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Net Change in Cash Chart

Neoleukin Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.90 66.17 50.34 -50.09 -104.58

Neoleukin Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.19 -2.45 -2.39 -4.75 -5.88

Neoleukin Therapeutics Net Change in Cash Calculation

Neoleukin Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-45.607+-59.134+0.161+0
=-104.58

Neoleukin Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.269+-1.614+-0.001+0
=-5.88

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neoleukin Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Net Change in Cash
Comparable Companies
SIOX MTEM LUMO INAB LTRN NERV UBX ALGS NXTC NRXP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102
Website
https://www.neoleukin.com
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Executives
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith officer: Principal Accounting Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel officer: Chief Medical Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle director C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener officer: General Counsel, SVP Legal C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar director 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman director, officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey officer: Senior Vice President C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho officer: Chief Financial Officer 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance officer: General Counsel C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle director 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Neoleukin Therapeutics (Neoleukin Therapeutics) Headlines

From GuruFocus

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA� (pembrolizumab)

By GuruFocusNews GuruFocusNews • 07-05-2022

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA� (pembrolizumab)

By GuruFocusNews GuruFocusNews • 05-26-2022

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA� (pembrolizumab)

By GuruFocusNews GuruFocusNews • 05-16-2022

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger -- NLTX, DEN, BG, SCU

By Marketwired • 08-21-2023

Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

By PurpleRose PurpleRose • 08-03-2022

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA� (pembrolizumab)

By GuruFocusNews GuruFocusNews • 06-15-2022

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq -- PRDS), Kaleyra, Inc. (NYSE -- KLR), Great Ajax Corp. (NYSE -- AJX)

By Marketwired • 07-18-2023

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

By Business Wire • 07-25-2023

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

By PurpleRose PurpleRose • 07-27-2022

Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

By GuruFocusNews GuruFocusNews • 07-08-2022